Filing Flows › Voyager Therapeutics (VYGR) › Q1 2026
Voyager Therapeutics (VYGR) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Voyager Therapeutics (VYGR) reported revenue of $2.6M for the first quarter 2026 (Q1 2026), -60% from a year earlier and -83% from the quarter before.
Voyager Therapeutics, Q1 2026: revenue $2.6M (-60% year over year), net loss $27.9M, operating cash flow −$33.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.6M | -83% | -60% |
| Operating profit | −$30.3M | — | — |
| Net earnings | −$27.9M | — | — |
| Operating cash flow | −$33.4M | — | — |
What changed
Revenue was $2.6M in Q1 2026, down 60% year over year and down 83% from the previous quarter.
Operating costs exceeded revenue by $30.3M, an operating margin of -1167.4%. Total costs fell 20% while revenue fell 60%. The quarter ended with a net loss of $27.9M, wider than the previous quarter's $27.4M loss.
Operating cash flow was −$33.4M. Non-cash charges added back $932K of depreciation and $2.5M of share-based compensation. Working capital and other items used $8.9M. Capital expenditures of $14K exceeded it, leaving free cash flow of −$33.4M.
Questions
What was Voyager Therapeutics' revenue in the first quarter 2026?
Voyager Therapeutics (VYGR) reported revenue of $2.6M for the first quarter 2026 (Q1 2026), -60% from a year earlier and -83% from the quarter before.